JP7285631B2 - BODY COOLANT AND METHOD FOR MAKING BODY COOLANT - Google Patents

Description

The present invention relates to a body coolant and a method of making a body coolant, and more particularly to a body coolant and a body coolant for extemporaneously preparing a body coolant for application to the skin. It relates to the manufacturing method etc. of

Icing is a first-aid treatment for injury or disease; prevention of injury during exercise; reduction of post-exercise muscle pain and accumulated fatigue; is to cool to These uses of icing are based on the following physiological effects (a) to (d) of icing.
(a) It rapidly constricts blood vessels and suppresses internal bleeding and inflammation.
(b) By reducing the blood flow and metabolism in the fatigued and damaged sites, the spread of fatigue and damage from the aforementioned sites to surrounding tissues is suppressed.
(c) numbing pain sensitive nerves;
(d) decrease the activity of intramuscular cells;

The effectiveness of icing has become more widely recognized than in the past and sprays for icing are widely available commercially. However, when icing is performed by the conventional method, the blood flow remains low for a relatively long time after the icing is finished, so there is a drawback that fatigue substances (lactic acid) accumulate and exercise performance declines. Therefore, when the icing is performed by the conventional method, a method such as warming the iced portion after the icing is completed is performed. However, this method has the drawback that it is difficult to ascertain how much heating should be done, and that excessive heating significantly reduces the effectiveness of the icing. Under these circumstances, there has been a demand for an icing method in which these drawbacks are improved.

By the way, a substance called _CO2 hydrate (carbon dioxide hydrate) is known as a _kind of ice with a high CO2 content. CO ₂ hydrate refers to clathrate compounds in which carbon dioxide molecules are confined in the voids of water molecule crystals. A water molecule that forms a crystal is called a "host molecule", and a molecule that is confined in the vacant space of the water molecule crystal is called a "guest molecule" or "guest substance". CO ₂ hydrate generates CO ₂ upon melting because it decomposes into CO ₂ (carbon dioxide) and water when melted. _CO2 hydrate can be produced by subjecting _{CO2 and} water to conditions of low temperature and high _CO2 partial pressure, e.g. It can be produced under conditions including a CO ₂ partial pressure higher than the equilibrium pressure of the rate (hereinafter also referred to as "CO ₂ hydrate production conditions"). The CO ₂ content of the CO ₂ hydrate can be about 3 to 28% by weight, depending on the method of producing the CO ₂ hydrate, and the CO ₂ content of carbonated water (about 0.5% by weight) ), significantly higher.

As an application of _CO2 hydrate, it is known to add and mix _CO2 hydrate with beverages. For example, Patent Document 1 discloses a method of producing carbonated beverages by mixing CO ₂ hydrate with a beverage to impart carbonic acid to the beverage, and Patent Document 2 discloses that CO ₂ hydrate is covered with ice. It is disclosed to cool a lukewarm beverage and to re-carbonate a flattened beverage by adding a carbonation medium formed by the method to the beverage. In addition, Patent Document 3 discloses a method for keeping _{cold any one of perishables, dairy products, unbaked sweets, and fresh flowers using CO 2 hydrate} . A method for keeping an object to be kept cold by storing the object in a sealable container without contacting the object is disclosed. In addition, Patent Document 4 discloses a cooling device that uses oxygen hydrate ( _O2 hydrate) to cool body parts of a bather and beverages for the bather to prevent hot flashes and realize a comfortable bathing environment. is disclosed.

However, it was not known that cooling the body with ice having a _CO2 content of 3% by weight or more, such as _CO2 hydrate, could cool the body while suppressing a decrease in blood flow. .

JP 2005-224146 A Patent No. 4969683 publication Japanese Patent No. 4500566 Japanese Patent Application Laid-Open No. 2007-319280

An object of the present invention is to provide a body cooling agent that can cool the body while suppressing a decrease in blood flow, and a method for producing a body cooling liquid that includes a step of bringing the body cooling agent into contact with a liquid. That's what it is.

In the course of intensive studies to solve the above problems, the present inventors brought ice (preferably CO ₂ hydrate) having a CO ₂ content of 3% by weight or more into contact with a liquid (preferably contained in the liquid The inventors have found that when the prepared low-temperature liquid is applied to the skin of the animal body, the body can be cooled while suppressing the decrease in blood flow in the skin, and the present invention has been completed.

That is, the present invention
(1) a body cooling agent characterized in that it contains ice with a _CO2 content of 3% by weight or more;
(2) The body cooling agent according to (1) above, wherein the ice having a _CO2 content of 3% by weight or more is a _CO2 hydrate;
(3) The above (1) or (2), wherein the ice with a _CO2 content of 3% by weight or more has a maximum length of 3 mm or more and a _CO2 content of 3% by weight or more. body cooling agent;
(4) Ice with a CO ₂ content of 3% by weight or more has a concentration of 5 million bubbles / mL or more when measured by the following measurement method R1. The body cooling agent according to any one of the above (1) to (3), characterized in that it is ice that can be generated in
(Measurement method R1)
300 mg/mL of ice having a temperature of −80 to 0° C. and having a CO ₂ content of 3% by weight or more is added to water at 25° C. to contain ice having a CO ₂ content of 3% by weight or more. After making ice water at 0 to 2 ° C., the concentration of ultra-fine bubbles (bubbles / mL) in the ice water is measured with Nanosite NS300 manufactured by Malvern;
(5) The body cooling agent according to any one of (1) to (4) above, wherein the ice having a CO ₂ content of 3% by weight or more is compacted CO ₂ hydrate; or
(6) The body cooling agent according to any one of the above (1) to (5), which is for preparing a body cooling liquid for application to the skin immediately before use;
Regarding.

In addition, the present invention
(7) A method for producing a body coolant for application to the skin, comprising the step of contacting the body coolant according to any one of (1) to (6) above with a liquid; or
(8) A liquid containing carbonic acid of 200 ppm or more and having a concentration of ultra-fine bubbles of 5 million bubbles/mL or more when measured by the following measurement method R1. coolant;
(Measurement method R1)
300 mg/mL of ice having a temperature of −80 to 0° C. and having a CO ₂ content of 3% by weight or more is added to water at 25° C. to contain ice having a CO ₂ content of 3% by weight or more. After making ice water at 0 to 2 ° C., the concentration of ultra-fine bubbles (bubbles / mL) in the ice water is measured with Nanosite NS300 manufactured by Malvern;
Regarding.

INDUSTRIAL APPLICABILITY According to the present invention, there are provided a body cooling agent that can cool the body while suppressing a decrease in blood flow, and a method for producing a body cooling liquid that includes a step of bringing the body cooling agent into contact with a liquid. be able to.

FIG _{. 2 is a diagram showing the particle size distribution and number concentration (cells/mL) of bubbles in ice water containing CO 2} hydrate. The horizontal axis of the graph represents the particle diameter (nm) of bubbles, and the vertical axis represents the number concentration of bubbles (cells/mL). FIG. 4 is a diagram showing the results of measuring blood flow in the tail of rats. The blood flow rate of the rat tail was measured for 30 minutes while the rat tail was immersed in ice water for each sample and for 30 minutes after the end of immersion. The horizontal axis of the graph represents the elapsed time (minutes) from the start of immersion of each sample in ice water of the tail, and the vertical axis of the graph represents the average value of blood flow for 5 minutes before the start of immersion when 100%. , represents the relative value (%) of blood flow. The relative value (%) of the blood flow shown in the graph was calculated using the average value of the blood flow for every 5 minutes. For example, the relative value of the blood flow 5 minutes after the start of immersion was calculated using the average value of the blood flow for 5 minutes after the start of immersion.

The present invention
[1] The body cooling agent according to claim 1, wherein the ice having a _CO2 content of 3% by weight or more (hereinafter also referred to as "high _CO2 content ice") is a _CO2 hydrate (hereinafter referred to as " It is also indicated as "the body cooling agent of the present invention".);
[2] A method for producing a body cooling liquid for application to the skin, comprising the step of bringing the body cooling agent of the present invention into contact with a liquid (hereinafter also referred to as the "production method of the present invention");
[3] A liquid containing 200 ppm or more of carbonic acid and having a concentration of ultra-fine bubbles of 5 million bubbles/mL or more when measured by the measurement method R1 (or R2) described later, and applied to the skin. body cooling liquid for (hereinafter also referred to as "body cooling liquid of the present invention");
[4] Cooling the body of an animal, including applying CO2 _- enriched ice (preferably _CO2 hydrate), the body cooling agent or body cooling liquid of the present invention to the animal's whole body or localized skin. method (hereinafter also referred to as "body cooling method of the present invention");
and other embodiments. In addition, in this specification, an "agent" can be rephrased as a "substance" or a "composition."

1. <Body cooling agent of the present invention>
(Ice with a _CO2 content of 3% by weight or more)
The body cooling agent of the present invention is not particularly limited as long as it contains ice with a _CO2 content of 3% by weight or more (" _CO2- rich ice"). Such CO2 _- rich ice may be _{CO2- rich} ice that is not _CO2 hydrate. It is preferably a rate, more preferably a compacted _CO2 hydrate. In addition, as the CO2 _- rich ice in the present invention, CO2 _- rich ice that is not a CO2 hydrate may be used without using a _CO2 hydrate, or _{CO2- rich} ice that is not a _CO2 hydrate may be used. CO 2 hydrate may be used without using CO ₂ hydrate, or CO ₂ -rich ice that is not CO ₂ hydrate may be used in combination with CO ₂ hydrate. In addition, as the _CO2 hydrate, non-consolidated _CO2 hydrate may be used instead of _using consolidated CO2 hydrate, or consolidated _CO2 hydrate may be used without using non-consolidated CO2 hydrate. ₂ hydrate may be used, or a combination of uncompacted CO ₂ hydrate and compacted CO ₂ hydrate may be used.

_CO2 hydrates are solid inclusion compounds that entrap carbon dioxide molecules in the voids of water molecule crystallites. CO ₂ hydrates are usually ice-like crystals, and when placed under, for example, standard atmospheric pressure conditions and temperature conditions such that ice melts, they release CO ₂ as they melt. As mentioned above, the _CO2- enriched ice used in the present invention is preferably a _CO2 -hydrate, and is preferably a compacted CO2 _{-hydrate, rather than a CO2- enriched} ice that is not a _CO2 hydrate. more preferred. The reason for this is that when the body cooling agent of the present invention is brought into contact with a liquid, _CO2 bubbles (preferably ultra-fine bubbles) can be obtained at a higher concentration, resulting in a higher blood flow suppression effect. This is because it is considered that (preferably, a blood flow maintenance effect) can be obtained. "Ultra-fine bubbles" are fine bubbles with a diameter of 1000 nm or less in a solvent such as water under normal pressure. Compared with ordinary bubbles having a diameter of 1 mm or more, such ultra-fine bubbles (1) have a remarkably large bubble interface surface area, (2) have a large internal bubble pressure, and (3) have a high gas dissolution efficiency. , and (4) a slow bubble rising speed. For the generation of such ultra-fine bubbles, _{an ultra- fine} bubble generator _is usually essential. Fine CO ₂ bubbles (preferably ultra-fine bubbles) can be easily generated without using a fine bubble generator.

As the CO _2- rich ice in the present invention, the concentration (pieces/mL) of ultra-fine bubbles (preferably CO ₂ ultra-fine bubbles) measured by the following measurement method R1 is preferably 5 million. /mL or more, more preferably 10 million/mL or more, more preferably 20 million/mL or more, more preferably 25 million/mL or more, still more preferably 30 million/mL or more, More preferably 35 million/mL or more, more preferably 50 million/mL or more, more preferably 75 million/mL or more, still more preferably 100 million/mL or more, more preferably 150 million/mL or more, more preferably 200 million/mL or more, more preferably 250 million/mL or more ultra-fine bubbles (preferably _CO2 ultra-fine bubbles) Preference may be given to CO ₂ -rich ice that can be generated in the ice.
(Measurement method R1)
300 mg/mL of ice having a temperature of −80 to 0° C. and having a CO ₂ content of 3% by weight or more is added to water at 25° C. to contain ice having a CO ₂ content of 3% by weight or more. After making ice water at 0 to 2° C., the concentration (bubbles/mL) of ultra-fine bubbles in the ice water is measured with Nanosite NS300 manufactured by Malvern.

The upper limit of the concentration of ultra-fine bubbles (preferably CO ₂ ultra-fine bubbles) that can be generated in water by the CO _2- rich ice of the present invention is not particularly limited, but the above-mentioned measurement method R1 For example, the concentration of ultra-fine bubbles measured at 10 billion/mL or less, or 1 billion/mL or less.

A more specific concentration of ultra-fine bubbles (preferably CO ₂ ultra-fine bubbles) that can be generated in water by the CO ₂ -rich ice of the present invention is 5 million to 10 billion bubbles/ mL, 5-1 billion/mL, 10-10 billion/mL, 10-1 billion/mL, 20-10 billion/mL, 20-1 billion/mL mL, 25-10 billion/mL, 25-1 billion/mL, 30-10 billion/mL, 30-1 billion/mL, 35 million 10,000 to 10 billion/mL, 35 to 1 billion/mL, 50 to 10 billion/mL, 50 to 1 billion/mL, 75 to 10 billion/mL mL, 75 million to 1 billion/mL, 100 million to 10 billion/mL, 100 million to 1 billion/mL, 150 million to 10 billion/mL, 150 million to 1 billion/mL, 200 million to 10 billion/mL, 200 million to 1 billion/mL, 250 million to 10 billion/mL, 250 million to 1 billion/mL, etc. be done.

The CO ₂ content of the CO 2 high content ice (preferably CO ₂ hydrate) in the present invention is not particularly limited as long as it is 3% by weight or more, but the _{CO 2 bubbles} (preferably ultra-fine bubbles) are higher. From the viewpoint of obtaining a higher blood flow reduction inhibitory effect (preferably, blood flow maintenance effect) at a concentration, it is preferably 5% by weight or more, more preferably 7% by weight or more, still more preferably 10% by weight or more, and more. It is preferably 13% by weight or more, more preferably 16% by weight or more, and more preferably 18% by weight or more. Although the upper limit is not particularly limited, it may be 30% by weight, 28% by weight, 26% by weight, or 24% by weight. More specific CO ₂ contents of CO ₂ -rich ice (preferably CO ₂ hydrate) are 5 to 30 wt%, 7 to 30 wt%, 10 to 30 wt%, 13 to 30 wt%, 16 ~30 wt%, 18-30 wt%, 5-28 wt%, 7-28 wt%, 10-28 wt%, 13-28 wt%, 16-28 wt%, 18-28 wt%, 5-26 wt% % by weight, 7 to 26% by weight, 10 to 26% by weight, 13 to 26% by weight, 16 to 26% by weight, 18 to 26% by weight, and the like.

The _CO2 content of the CO2 _- rich ice in the present _invention can be adjusted by "high or low _{CO2 partial pressure" when producing the CO2- rich} ice in the present invention. If higher, the CO2 content of the _{CO2 -} enriched ice can be increased. In addition, when the CO ₂ high content ice is CO ₂ hydrate, "high or low CO ₂ partial pressure", "degree of dehydration treatment", "whether or not to perform compression treatment" when producing CO ₂ hydrate ”, “High or low compression pressure in the case of compression processing”, etc., can adjust the CO ₂ content of the CO ₂ hydrate. For example, "increase _{the CO2} partial pressure", "increase the degree of dehydration treatment", "perform compression treatment", and "increase the pressure of consolidation in the case of compression treatment" when producing CO2 hydrate. , the _CO2 content of the _CO2 hydrate can be increased. Note that when the CO2 _- rich ice such as _CO2 hydrate melts, the _CO2 contained in the CO2 _- rich ice such as the _CO2 hydrate is released, and the weight of that amount decreases. The _CO2 content of the CO2 _- rich ice such as ₂ hydrate can be obtained, for example, from the weight change when the CO2 _- rich ice such as _CO2 hydrate is melted at room temperature, using the following formula (1): can be calculated.
(CO ₂ content) = (Sample weight before melting - Sample weight after melting) / Sample weight before melting) …… Equation (1)

In addition, all of the CO2 _- rich ice (preferably _CO2 hydrate) contained in the body cooling agent of the present invention preferably has a _CO2 content of 3% by weight or more, but the effect of the present invention Ice and CO ₂ hydrate with a CO ₂ content of less than 3% by weight may also be contained within the range where (the effect of cooling the body while suppressing the decrease in blood flow) can be obtained. The ratio (% by weight) of ice _{or CO2} hydrate with a _CO2 content of less than 3% by weight to the CO2-rich ice (preferably _CO2 hydrate) contained in the body cooling agent of the present invention is 10 % by weight or less, preferably 5% by weight or less, more preferably 3% by weight or less, and even more preferably 1% by weight or less.

The shape of the CO _2- rich ice (preferably CO ₂ hydrate) in the present invention can be appropriately set, for example, a substantially spherical shape; a substantially ellipsoidal shape; and the like. In addition, the CO ₂ -rich ice (preferably CO ₂ hydrate) in the present invention is crushed pieces (clumps) of various shapes obtained by appropriately crushing blocks of CO ₂ -rich ice (preferably CO ₂ hydrate). ).

The size of the CO ₂ -rich ice (preferably CO ₂ hydrate) in the present invention is not particularly limited and can be set as appropriate. The lower limit of the maximum length of the CO2 _- rich ice (preferably _CO2 hydrate) in the present invention is preferably 3 mm or more, more preferably 5 mm or more, still more preferably 7 mm or more, and more preferably 10 mm or more. The upper limit of the length includes 150 mm or less, 100 mm or less, 80 mm or less, and 60 mm or less. 5 mm to 100 mm, 5 mm to 80 mm, 5 mm to 60 mm, 10 mm to 150 mm, 10 mm to 100 mm, 10 mm to 80 mm, and 10 mm to 60 mm.

As used herein, the term "maximum length of ice with high _CO2 content" refers to the longest line segment among the line segments that connect two points on the surface of the block of ice with high _CO2 content and pass through the center of gravity of the block. means the length of When the CO2 _- rich ice is, for example, approximately ellipsoidal, the maximum length represents the major axis (longest diameter), and when approximately spherical, the maximum length represents the diameter. If present, it represents the length of the longest diagonal. In this specification, the "minimum length of ice with high _CO2 content" means connecting two points on the surface of the block of ice with high _CO2 content (preferably _CO2 hydrate), and the center of gravity of the block It means the length of the shortest line segment among the line segments passing through. Such maximum length and minimum length can be measured using a commercially available image analysis type particle size distribution analyzer or the like, or measured by applying a ruler to a mass of CO _2- rich ice (preferably CO ₂ hydrate). can also

As a preferred embodiment of the CO _2- rich ice (preferably CO ₂ hydrate) in the present invention, the aspect ratio (maximum length / minimum length) is preferably within the range of 1 to 5, more preferably within the range of 1 to 4 , and more preferably CO ₂ -rich ice (preferably CO ₂ hydrate) in the range of 1-3.

The size of CO2 _- enriched ice (preferably _CO2 hydrate) can be adjusted in the following manner. For example, the maximum length of CO2 _- enriched ice that is not _CO2 hydrate can be adjusted by adjusting the maximum length of the mold when producing such CO2 _- enriched ice, or when crushing CO2 _- enriched ice after production. can be adjusted by adjusting the degree of crushing. In addition, the maximum length of the _CO2 hydrate can be adjusted by adjusting the maximum length of the mold used when compression molding the _CO2 hydrate, or by adjusting the degree of crushing when crushing the _CO2 hydrate after compression molding. You can adjust by doing Also, the minimum length can be adjusted by adjusting the minimum length of the mold or by adjusting the degree of crushing of the high _CO2 content ice after production.

The method for producing CO ₂ -rich ice in the present invention is not particularly limited as long as the CO ₂ -rich ice can be produced. As a method for producing CO2 _- rich ice that is not _CO2 hydrate, there is a method of freezing raw water while blowing _CO2 into raw water under conditions that do not satisfy the conditions for _producing CO2 hydrate. In addition, as a method for producing CO ₂ hydrate, there is a gas-liquid stirring method in which raw water is stirred while _{CO 2} is blown into raw water under conditions that satisfy the conditions for producing CO 2 hydrate, and a method that satisfies the conditions for producing CO ₂ hydrate. A conventional method such as a water spray method in which raw material water is sprayed into CO ₂ under certain conditions can be used. The _CO2 hydrate produced by these methods is usually in the form of a slurry _in which fine particles of _CO2 hydrate are mixed with unreacted water. Treatment is preferred. _CO2 hydrate with relatively low water content due to dehydration (i.e., relatively high-concentration _CO2 hydrate) can be compression-molded into a certain shape (e.g., spherical or rectangular parallelepiped) by a pelletizer. preferable. Compression-molded CO ₂ hydrate can be suitably used as one type of compacted CO ₂ hydrate in the present invention. The compression-molded CO ₂ hydrate may be used in the present invention as it is, or may be further crushed and used as necessary. As a method for producing _CO2 hydrate, as described above, the method using raw material water is relatively widely used _. and CO _{2 hydrate under the conditions of low temperature and low CO 2 partial} pressure.

The above-mentioned " _CO2 hydrate production condition" is, as described above, a condition in which the _CO2 partial pressure ( _CO2 pressure) is higher than the equilibrium pressure of _CO2 hydrate at that temperature. The above "conditions in which the _CO2 partial pressure is higher than the equilibrium pressure of the _CO2 hydrate" are shown in Figure 2 of J. Chem. Eng. Data (1991) 36, 68-71 and J. Chem. Eng. Data (2008), 53, 2182-2188, Figure 7 and Figure 15 of CO ₂ hydrate equilibrium pressure curves (for example, the vertical axis represents CO ₂ pressure and the horizontal axis represents temperature). (in the equilibrium pressure curve of _CO2 hydrate, for example, when the vertical axis represents _CO2 pressure and the horizontal axis represents temperature, above the curve) as a condition for the combination of _CO2 pressure and temperature expressed. Specific examples of CO ₂ hydrate generation conditions include a combination of "within the range of -20 to 4°C" and "within the range of carbon dioxide pressure of 1.8 to 4 MPa", and "within the range of -20 to -4°C conditions of a combination of "within" and "within the carbon dioxide pressure range of 1.3 to 1.8 MPa".

The content of CO _2- rich ice (preferably CO ₂ hydrate) in the body cooling agent of the present invention is not particularly limited, but is, for example, within the range of 5 to 100% by weight, preferably within the range of 30 to 100% by weight. Among them, more preferably in the range of 50 to 100% by weight, more preferably in the range of 70 to 100% by weight.

In the present invention, "consolidated CO ₂ hydrate" means that the CO ₂ hydrate rate is 40 to 90% (preferably 50 to 90%, more preferably 60 to 90%, still more preferably 70 to 90%, more preferably means CO ₂ hydrate that is 80-90%). _CO2 hydrate ratio means the ratio (%) of the weight of _CO2 hydrate to the weight of the _CO2 hydrate mass. Such a CO ₂ hydrate rate can be calculated by the following formula (2).
CO ₂ hydrate rate (%) = {(sample weight before melting - sample weight after melting) + (sample weight before melting - sample weight after melting) / 44 x 5.75 x 18} x 100 / melting Previous sample weight …… Equation (2)
Equation (2) is explained below. (Sample weight before thawing - Sample weight after thawing) becomes the CO ₂ gas weight occluded. The amount of water required to clathrate _CO2 gas as a hydrate was calculated using a theoretical hydration number of 5.75, a molecular weight of _CO2 of 44, and a molecular weight of water of 18. Other water constitutes a hydrate. Do not regard it as adhering water.

The compacted CO ₂ hydrate suitable for the present invention has a concentration (number/mL) of ultra-fine bubbles measured by the aforementioned measurement method R1 of 50 million/mL or more, more preferably 7,500. 10,000/mL or more, more preferably 100 million/mL or more, more preferably 150 million/mL or more, still more preferably 200 million/mL or more, more preferably 250 million/mL _CO2 hydrate that can generate the above ultra-fine bubbles in water. In addition, as for the CO ₂ content of the compacted CO ₂ hydrate suitable for the present invention, ultra-fine bubbles can be obtained at a higher concentration to obtain a higher blood flow reduction inhibitory effect (preferably, blood flow maintenance effect). From the viewpoint, it is preferably 7% by weight or more, more preferably 10% by weight or more, still more preferably 13% by weight or more, more preferably 16% by weight or more, and still more preferably 18% by weight or more. Although the upper limit is not particularly limited, 30% by weight, 28% by weight, 26% by weight, and 24% by weight can be mentioned. More specific CO ₂ contents of suitable compacted CO ₂ hydrates in the present invention are 7-30 wt%, 10-30 wt%, 13-30 wt%, 16-30 wt%, 18-30 wt%, % by weight, 7-28% by weight, 10-28% by weight, 13-28% by weight, 16-28% by weight, 18-28% by weight, 7-26% by weight, 10-26% by weight, 13-26% by weight , 16 to 26% by weight, 18 to 26% by weight, and the like.

The method for producing the compacted CO ₂ hydrate in the present invention is not particularly limited, but the following production method can be mentioned, for example.
A gas _- liquid stirring method in which the raw water is stirred while blowing _CO2 into the raw water under conditions that satisfy the _CO2 hydrate generation conditions, and a raw water that is sprayed into the _CO2 under conditions that satisfy the CO2 hydrate generation conditions. A conventional method such as a water spray method can be used. The CO ₂ hydrate produced in these manners is typically in the form of a slurry of fine particles of CO ₂ hydrate mixed with unreacted water. Consolidated CO ₂ hydrate can be produced by subjecting such slurry to dehydration treatment and compression treatment. The dehydration treatment and compression treatment of the slurry containing CO ₂ hydrate particles and water are carried out by performing dehydration treatment and compression treatment separately in sequence, for example, performing dehydration treatment of the slurry and then performing compression treatment of the CO ₂ hydrate particles. Alternatively, the dehydration treatment and compression treatment may be performed at the same time by compressing the slurry under conditions where the water in the slurry can be discharged, but the ultra-fine bubbles can be obtained at a higher concentration. Therefore, from the viewpoint of obtaining a higher effect of suppressing blood flow reduction (preferably, effect of maintaining blood flow), it is preferable to perform _dehydration treatment and compression treatment at the same time. are more preferably performed at the same time. Compression processing of CO ₂ hydrate particles and compression processing of slurry can be performed using a commercially available compaction molding machine or the like. Examples of the pressure for compression treatment include 1 to 100 Mpa, 1 to 50 Mpa, 1 to 30 Mpa, 1 to 15 Mpa, 1 to 10 Mpa, 2.5 to 10 Mpa, and 2.5 to 9 Mpa. It should _be noted _that when the above-mentioned slurry is subjected to sufficient dehydration treatment, the CO ₂ hydrate rate is usually about 40%. The rate rate is usually about 60%, and when the CO ₂ hydrate particles are compressed at 9 Mpa after dehydration, the CO ₂ hydrate rate is generally about 90%.

The CO2 _- rich ice (preferably CO2 hydrate ₎ in the body cooling agent of the present invention is CO2 _- rich ice (preferably _CO2 hydrate) consisting only of _CO2 and ice (hereinafter referred to as "optional ingredients CO _2- rich ice (preferably CO _{2 hydrate)” that does not contain CO 2-} rich ice (preferably CO 2 hydrate)”, which further contains optional ingredients according to the use of the body cooling agent (preferably CO ₂ -rich ice) ₂ hydrate). In addition, the body cooling agent of the present invention is " _CO2 -rich ice (preferably CO2 hydrate) containing no optional ingredients" or " _{CO2- rich} ice (preferably _CO2 hydrate) containing optional ingredients". It may be a body cooling agent that consists of only "ice (preferably _CO2 hydrate)", or may further contain optional ingredients in addition to these CO2-rich ice (preferably _CO2 hydrate).

When the body cooling agent of the present invention contains CO ₂ -rich ice other than CO ₂ hydrate, the body cooling agent of the present invention should be maintained at a temperature and pressure at which the ice does not melt during distribution and storage. is preferred. Examples of such temperature and pressure include normal pressure (eg, 1 atm) and 0° C. or less. On the other hand, some CO ₂ hydrates are excellent in storage stability and stability depending on the production method and the like. Therefore, when the body cooling agent of the present invention contains CO ₂ hydrate as CO ₂ -rich ice, the body cooling agent of the present invention can be stored at room temperature (5 to 35°C) and under normal pressure during distribution and storage. (For example, 1 atmospheric pressure), but from the viewpoint of keeping the body cooling agent of the present invention more stable for a longer period of time, the body cooling agent of the present invention should be kept at a "low temperature" during distribution, storage, etc. It is preferable to keep under "low temperature and high pressure conditions", or "under high pressure conditions". From the viewpoint of ease of maintenance, among these, it is preferable to maintain under "low temperature conditions", and more preferable to maintain under "low temperature conditions" at normal pressure (for example, 1 atm).

The upper limit temperature in the above "low temperature conditions" is 10° C. or less, preferably 5° C. or less, more preferably 0° C. or less, still more preferably −5° C. or less, more preferably −10° C. or less, further preferably − 15°C or lower, more preferably -20°C, and more preferably -25°C. 40° C. or higher, −30° C. or higher, and the like.

The lower limit pressure under the above-mentioned "high pressure conditions" includes 1.036 atmospheres or more, preferably 1.135 atmospheres or more, more preferably 1.283 atmospheres or more, and still more preferably 1.480 atmospheres or more. Examples of the upper limit pressure under "high pressure conditions" include 14.80 atmospheres or less, 11.84 atmospheres or less, 9.869 atmospheres or less, 7.895 atmospheres or less, and 4.935 atmospheres or less.

The body cooling agent of the present invention may be contained in a container. The shape and material of the container are not particularly limited, and examples thereof include a plastic bottle container.

As for the body cooling agent of the present invention, the concentration (cells/mL) of ultra-fine bubbles measured by the following measurement method R2 is preferably 5 million cells/mL or more, more preferably 10 million cells/mL. above, more preferably 20 million/mL or more, more preferably 25 million/mL or more, still more preferably 30 million/mL or more, more preferably 35 million/mL or more, More preferably 50 million/mL or more, more preferably 75 million/mL or more, still more preferably 100 million/mL or more, more preferably 150 million/mL or more, still more preferably Body cooling agents capable of generating 200 million/mL or more, more preferably 250 million/mL or more ultra-fine bubbles in water can be preferably used. In addition, the upper limit of the concentration of ultra-fine bubbles (preferably _CO2 ultra-fine bubbles) that can be generated in water by the body cooling agent of the present invention is not particularly limited, but the following measurement method R2 For example, the concentration of ultra-fine bubbles measured at 10 billion/mL or less, or 1 billion/mL or less. More specific concentrations of ultra-fine bubbles (preferably _CO2 ultra-fine bubbles) that the body cooling agent of the present invention can generate in water are 5 million to 10 billion bubbles/mL, 5-1 billion/mL, 10-10 billion/mL, 10-1 billion/mL, 20-10 billion/mL, 20-1 billion/mL, 25 million to 10 billion/mL, 25 million to 1 billion/mL, 30 million to 10 billion/mL, 30 million to 1 billion/mL, 35 million to 10 billion/mL, 35-1 billion/mL, 50-10 billion/mL, 50-1 billion/mL, 75-10 billion/mL, 75 million to 1 billion/mL, 100 million to 10 billion/mL, 100 million to 1 billion/mL, 150 million to 10 billion/mL, 150 million to 1 billion 200 million to 10 billion/mL, 200 million to 1 billion/mL, 250 million to 10 billion/mL, and 250 million to 1 billion/mL.
(Measurement method R2)
300 mg/mL of a body cooling agent at -80 to 0°C converted to ice with a _CO2 content of 3% by weight or more is added to water at 25°C, and the ice has a _CO2 content of 3% by weight or more. After making ice water at 0 to 2° C. containing , the concentration of ultra-fine bubbles (bubbles/mL) in the ice water is measured with Nanosite NS300 manufactured by Malvern.

(How to use the body cooling agent)
The method of using the body cooling agent of the present invention will be described in detail in the section "Method for producing the body cooling liquid of the present invention" below. A preferred method is to prepare a body coolant (incorporation into a liquid) and apply the body coolant to the skin (ie, contact the skin). That is, it is preferable that the body cooling agent of the present invention is for extemporaneously preparing a body cooling liquid for application to the skin. When the body cooling agent of the present invention is applied to the skin of an animal as the body cooling liquid, it can remarkably promote blood flow in the skin. A person skilled in the art will know the content of _CO2- rich ice (preferably CO2 hydrate) in the body cooling agent of the present invention and the _{CO2- rich} ice (preferably CO2 ₂ hydrate), the required concentration of ultra-fine bubbles, etc., the amount of the body cooling _agent used in the present invention can be adjusted.

(liquid)
The “liquid” in the present invention means that when the CO2 _- rich ice (preferably _CO2 hydrate) is contained in the liquid, the CO2 _- rich ice (preferably _CO2 hydrate) contains _CO2 . It is not particularly limited as long as it is a liquid that can generate bubbles (preferably ultra-fine bubbles) and may be brought into contact with the animal's skin, for example, (i) "hydrophilic solvent", (ii) " (iii) "a mixed solvent of a hydrophilic solvent and a hydrophobic solvent"; The temperature conditions and pressure conditions under which the “liquid” in the present invention is in a liquid form are affected by the type of solvent, the application of the liquid, the conditions of use of the liquid, etc., and cannot be specified unconditionally. Liquids that are liquid under atmospheric pressure conditions are preferred.

The "hydrophilic solvent" used in the present invention preferably has a solubility parameter (SP value) of 20 or more, more preferably 29.9 or more. Specifically, it is preferable to use one or more selected from the group consisting of water (47.9), polyhydric alcohols and lower alcohols. Dihydric alcohols such as ethylene glycol (29.9), diethylene glycol (24.8), triethylene glycol (21.9), tetraethylene glycol (20.3), and propylene glycol (25.8) as polyhydric alcohols , Trihydric alcohols such as glycerin (33.8), diglycerin, triglycerin, polyglycerin, and trimethylolpropane; tetravalent or higher alcohols such as diglycerin, triglycerin, polyglycerin, pentaerythritol, and sorbitol; Examples include hexitol, aldoses such as glucose, compounds having a sugar skeleton such as sucrose, pentaerythritol, and the like. Lower alcohols include isopropanol (23.5), butyl alcohol (23.3), ethyl alcohol (26.9). These hydrophilic solvents may be used in combination of two or more. The value in parenthesis indicates the δ value of the solubility parameter. A preferred hydrophilic solvent in the present invention preferably contains at least water, more preferably water.

The "hydrophobic solvent" used in the present invention is preferably an organic solvent having a solubility parameter (SP value) of less than 20.0. is a mixture of Examples of hydrocarbon solvents include hexane (14.9), heptane (14.3), dodecane (16.2), cyclohexane (16.8), methylcyclohexane (16.1), octane (16.0). , aliphatic hydrocarbons such as hydrogenated triisobutylene, aromatic hydrocarbons such as benzene (18.8), toluene (18.2), ethylbenzene (18.0), xylene (18.0), chloroform (19. 3), 1,2-dichloroethane (19.9), trichlorethylene (19.1) and other halogen-based hydrocarbons can be exemplified, and examples of silicone-based solvents include octamethylcyclotetrasiloxane, decamethylcyclopenta Examples include siloxane, hexamethyldisiloxane, octamethyltrisiloxane, and the like. Among these, hexane (14.9) and cyclohexane (16.8) are particularly preferred. These hydrophobic solvents may be used in combination of two or more.

As the "solute" in the above "liquid containing any solute in any of the solvents (i) to (iii)", the liquid contains CO _2- rich ice (preferably CO ₂ hydrate) There is no particular limitation as long as the CO ₂ -rich ice (preferably CO ₂ hydrate) can generate CO ₂ bubbles (preferably ultra-fine bubbles) when cooled. Specific examples of the "liquid containing any solute in any one of the solvents (i) to (iii)" include physiological saline.

(Optional component)
The body cooling agent of the present invention contains CO _2- rich ice as an essential ingredient, but as long as the effect of the present invention (the effect of cooling the body while suppressing the decrease in blood flow) is not impaired, optional ingredients may further contain. Examples of such optional components include components having medicinal effects, additives, and the like. Examples of components having such medicinal effects include other body cooling agents, antibiotics, analgesics, antiphlogistic agents, etc. Examples of the above additives include perfumes, coloring agents, thickeners, pH adjusters, and the like. .

(applicable target)
The animal to which the body cooling agent or body cooling liquid of the present invention is applied is not particularly limited, but preferably an animal belonging to any class selected from the group consisting of mammals, birds, reptiles, amphibians and fish. Among them, animals belonging to mammals or birds are more preferable, and animals belonging to mammals are more preferable, and humans, dogs, cats, horses, ponies, donkeys, cows, pigs, sheep, and goats. , rabbits, monkeys, mice, rats, hamsters, guinea pigs, ferrets and the like are more preferable, and humans and horses are more preferable, and humans are particularly preferable. Thoroughbreds, which are racehorses, are preferably exemplified as the above-mentioned horses. This is because it is common practice for racehorses to cool their legs with ice water after a race. Cooling of racehorses is widely practiced because racehorses were bred to run fast, and as a result, their legs are long and slender compared to their physiques, and they often break their legs during racing or training. and tendon injuries are common, and modern racehorse races are so fast that racehorses are very tired after a race.

Application of the body cooling agent or body cooling liquid of the present invention is not particularly limited as long as the animal to which it is applied requires a body cooling action. More specific uses of the body cooling agent of the present invention include, for example, a cooling agent for icing the body before, during, and after exercise; cooling agents; cooling agents for body cooling during fever; and the like.

(Applicable part)
The application site of the body cooling agent or body cooling liquid of the present invention includes the whole body or local skin of an animal. As used herein, the term “whole body” means the whole body within a range where the animal can breathe. means immersion in liquid. In the present specification, the local part is not particularly limited as long as it is a part of the body, and includes the head, face, neck, shoulders, arms, hands, chest, abdomen, buttocks, legs, feet, and the like. The body coolant or body coolant of the present invention may be applied simultaneously to multiple parts of the body. The term “skin” as used herein is not particularly limited as long as it is animal skin, and for the sake of convenience, animal mucous membranes are also included. Such mucous membranes include the lips, oral mucosa, and the like.

(Method of applying)
As a method for applying the body cooling agent of the present invention, the body cooling agent of the present invention may be directly applied to the skin of the application site, but the method of applying the body cooling liquid of the present invention to the skin of the application site is preferable. More specifically, preferable examples include a method of immersing the skin at the application site in the body cooling liquid of the present invention, a method of applying the body cooling liquid of the present invention to the skin at the application site, and the like. Among them, the method of immersing the skin of the application site in the body cooling liquid of the present invention is more preferable. The amount (preferably added amount) (mg/mL) of the CO ₂ -rich ice used for preparing the body cooling liquid of the present invention is as described in the item of the manufacturing method of the present invention.

(Temperature during use)
When the body cooling liquid of the present invention is applied to the skin, the temperature of the body cooling liquid can be appropriately set according to the condition of the body part to be cooled, the purpose of cooling, etc. For example, 0 to 10. °C, 0-8°C, 0-6°C, 0-4°C, 0-3°C, 0-2°C, 2-10°C, 2-8°C, 2-6°C, 2-4°C, 4-10 ℃, 4 to 8 ℃, 4 to 6 ℃, and the like. The method of adjusting the temperature of the body cooling liquid is not particularly limited, and for example, a method of adjusting the temperature of the liquid brought into contact with the body cooling liquid, or a method of adjusting the temperature of the body cooling liquid with a cooling device or a heating device. method. Commercially available products can be used as such a cooling device and a heating device.

The CO2 _- rich ice (preferably _CO2 hydrate) in the body cooling agent of the present invention is usually solid, and when the CO2 _- rich ice is brought into contact with a liquid to prepare a body cooling liquid, When the CO2 _- rich ice partly melts or melts, it takes a lot of heat out of the liquid, so the temperature of the liquid usually drops relatively large. Therefore, when the body coolant of the present invention is brought into contact with a liquid to prepare the body coolant, it is preferred to use the liquid at a temperature higher than the desired temperature of the body coolant. For example, it is preferable to use a liquid whose temperature is 2° C. or higher, 4° C. or higher, or 6° C. or higher than the desired temperature of the body cooling liquid to be prepared. Moreover, the body cooling liquid of the present invention is preferably prepared just before use when applied to the skin, from the viewpoint of obtaining a higher effect of suppressing a decrease in blood flow (preferably, an effect of maintaining blood flow). As used herein, "prepared just before use" includes, for example, 1 Within hours, preferably within 40 minutes, more preferably within 30 minutes, even more preferably within 20 minutes, more preferably within 10 minutes, and even more preferably within 5 minutes, the body cooling of the present invention preparation of liquids.

(Applicable time)
The application time of the body cooling agent or body cooling liquid of the present invention is not particularly limited as long as the effect of the present invention (the effect of cooling the body while suppressing the decrease in blood flow) can be obtained. It can be appropriately set according to the condition of the part, the purpose of cooling, the temperature of the cooling liquid for the body, etc. ˜20 minutes, 5-15 minutes, 10-20 minutes, 10-15 minutes.

(Frequency of application)
The frequency of application of the body cooling agent or body cooling liquid of the present invention is not particularly limited, and may be appropriately determined based on the improvement of symptoms, for example, about once to three times a day to three days. mentioned.

(blood flow reduction inhibitory effect)
In the present specification, the body cooling agent (or CO2 _- rich ice) of the present invention "has a blood flow suppression effect" (or the body cooling liquid of the present invention "has a blood flow suppression effect" ), the body cooling liquid (or the body cooling liquid of the present invention) obtained by contacting the body cooling agent (or CO2 _- rich ice) of the present invention with a liquid is placed in a room at 24 ° C. After 5 minutes (preferably after 10 minutes) from the start of application to the skin of the animal (preferably, immersing the skin of the animal in the body cooling liquid described above in a room at 24 ° C.) , more preferably after 15 minutes), the above-mentioned skin blood flow (hereinafter also referred to as "blood flow in the present invention") is 24 Start applying to the skin of the same part of the same animal as the above-mentioned animal in a room at 24 ° C. (preferably, immersing the animal skin in the above-mentioned ice water or water in a room at 24 ° C.) 5 minutes after (preferably after 10 minutes, more preferably after 15 minutes) the above-mentioned skin blood flow (hereinafter also referred to as "control blood flow"). Preferably, the blood flow in the present invention is higher than the control blood flow by 5% or more, more preferably 10% or more, still more preferably 15% or more, and more preferably 20% or more.

2. <Method for producing body cooling liquid of the present invention>
As the method for producing the body cooling liquid of the present invention (the production method of the present invention), "ice with a CO ₂ content of 3% by weight or more (preferably CO ₂ hydrate)" (or "body cooling liquid of the present invention agent") is not particularly limited as long as it includes a step of contacting the liquid. A body cooling liquid containing _CO2 bubbles (preferably ultra-fine bubbles) can be produced by contacting _{CO2 -} enriched ice (preferably CO2 hydrate) with a liquid.

The "body cooling liquid" used herein is not necessarily limited to all liquids, but also includes a mixture of solid CO2 _- rich ice (preferably _CO2 hydrate) and liquids. .

As used herein, the method of "contacting _ice with a _CO2 content of 3% by weight or more (preferably _CO2 hydrate) with a _liquid " includes It is not particularly limited as long as it is in contact, and a method of incorporating CO2 _- rich ice (preferably _CO2 hydrate) into a liquid is preferable, and among them, CO2 _- rich ice (preferably _CO2 hydrate) to a liquid, and a method of adding _{or charging} a liquid to CO2 _- rich ice (preferably _CO2 hydrate). More preferably, the method of adding or throwing the rate) into the liquid is exemplified.

The amount of CO2 _- rich ice used (preferably the amount added) (mg/mL) in the production method of the present invention depends on whether the CO2 _- rich ice is _CO2 hydrate or whether it is compacted _CO2 hydrate. Depending on whether there is, the _CO2 content of the CO2 _- rich ice, or how much concentration of _CO2 bubbles (preferably ultra-fine bubbles) is required, a person skilled in the art can set as appropriate be able to. The lower limit of the amount (preferably added amount) (mg/mL) of CO2 _- rich ice is, for example, 10 mg/mL or more, and _CO2 bubbles (preferably ultra-fine bubbles) are obtained at a higher concentration. From the viewpoint, it is preferably 20 mg/mL or more, more preferably 50 mg/mL or more, still more preferably 100 mg/mL or more, more preferably 150 mg/mL or more, still more preferably 200 mg/mL or more. In addition, the upper limit of the amount (preferably added amount) (mg/mL) of CO _2- rich ice is not particularly limited, but for example, 5000 mg/mL or less, 3000 mg/mL or less, 2000 mg/mL or less, 1000 mg/mL Below, 500 mg/mL or less is mentioned. More specific examples of the amount of CO ₂ high content ice used (preferably added amount) (mg/mL) are 20 to 5000 mg/mL, 20 to 3000 mg/mL, 20 to 2000 mg/mL, 50 to 2000 mg/mL, 50-1000 mg/mL, 100-500 mg/mL, 150-500 mg/mL. The amount of CO ₂ -rich ice used (mg/mL) means the weight (mg) of CO ₂ -rich ice used (preferably added) per 1 mL of liquid.

The temperature of the liquid when the CO _2- rich ice is brought into contact with the liquid is not particularly limited as long as CO ₂ bubbles (preferably ultra-fine bubbles) are generated. ~25°C, 0-20°C, 0-15°C, 0-10°C, 0-7°C, 0-5°C, 3-50°C, 3-35°C, 3-25°C, 3-15°C, 3 ~10°C, 3-7°C, 3-5°C, 6-50°C, 6-35°C, 6-25°C, 6-20°C, 6-15°C, 6-10°C, 6-7°C, 10 50° C., 10 to 35° C., 10 to 25° C., 10 to 15° C., etc., but those skilled in the art can appropriately set the temperature depending on the desired temperature of the body cooling liquid. The CO2 _- enriched ice (preferably _CO2 hydrate) in the body coolant of the present invention is usually solid, and when the _CO2 -enriched ice is brought into contact with a liquid to prepare the body coolant, the _CO2 The temperature of the liquid usually drops by a relatively large amount due to the removal of a lot of heat from the liquid when part or melt of the high content ice. Therefore, when the body coolant of the present invention is brought into contact with a liquid to prepare the body coolant, it is preferred to use the liquid at a temperature higher than the desired temperature of the body coolant. For example, a liquid having a temperature 2°C or higher, 4°C or higher, or 6°C or higher, preferably 2 to 10°C, 4 to 10°C, 6 to 10°C higher than the desired temperature of the body cooling liquid to be prepared. It is preferred to use liquids.

3. <Body cooling liquid of the present invention>
The body coolant of the present invention is a body coolant for application to the skin. The body cooling liquid of the present invention is a liquid containing 200 ppm or more of carbonic acid, and having a concentration of 5 million or more ultra-fine bubbles/mL when measured by the aforementioned measurement method R1 (or R2). Although it is not particularly limited as long as it is a body cooling liquid produced by the production method of the present invention, it is preferable.

As described above, the "body cooling liquid" in this specification is not necessarily limited to all liquids, but a mixture of solid CO2 _- rich ice (preferably _CO2 hydrate) and liquid. included in some cases.

The body cooling liquid of the present invention is not particularly limited as long as it contains 200 ppm or more of carbonic acid, preferably 500 ppm (0.05% by weight) or more, more preferably 750 ppm (0.075% by weight) or more, and still more preferably It preferably contains 900 ppm (0.09% by weight) or more, more preferably 1000 ppm (0.1% by weight) of carbonic acid. Although the upper limit of carbonic acid is not particularly limited, for example, 4000 ppm (0.4 wt%) or less, 3000 ppm (0.3 wt%) or less, 2000 ppm (0.2 wt%) or less, 1500 ppm (0.15 wt%) or less mentioned. More specifically, the carbonic acid concentration in the body cooling liquid of the present invention is 500 to 4000 ppm, 750 to 4000 ppm, 900 to 4000 ppm, 1000 to 4000 ppm, 500 to 3000 ppm, 750 to 3000 ppm, 900 to 3000 ppm, 1000 to 3000 ppm, 500. ~2000ppm, 750-2000ppm, 900-2000ppm, 1000-2000ppm, 500-1500ppm, 750-1500ppm, 900-1500ppm, 1500-2000ppm and the like.

The carbonic acid concentration in the body cooling liquid of the present invention means the concentration measured at a liquid temperature of 0 to 2° C. and normal pressure.

The concentration of ultra-fine bubbles (preferably _CO2 ultra-fine bubbles) in the body cooling liquid of the present invention is 5 million bubbles/mL when measured by the aforementioned measurement method R1 (number/mL). It is not particularly limited as long as it is above, but preferably 10 million/mL or more, more preferably 20 million/mL or more, still more preferably 25 million/mL or more, more preferably 30 million /mL or more, more preferably 35 million/mL or more, more preferably 50 million/mL or more, still more preferably 75 million/mL or more, more preferably 100 million/mL or more , more preferably 150 million/mL or more, more preferably 200 million/mL or more, still more preferably 250 million/mL or more. In addition, the upper limit of the concentration of ultra-fine bubbles (preferably _CO2 ultra-fine bubbles) in the body cooling liquid of the present invention is not particularly limited, but when measured by the above-described measurement method R1, the ultra-fine bubbles ( Preferably, the concentration of CO ₂ (ultra-fine bubbles) is, for example, 10 billion/mL or less, or 1 billion/mL or less. As a more specific concentration of ultra-fine bubbles (preferably _CO2 ultra-fine bubbles) in the body cooling liquid of the present invention, the concentration when measured by the above-described measurement method R1 (or R2) (number/mL ), 5-10 billion/mL, 5-1 billion/mL, 10-10 billion/mL, 10-1 billion/mL, 20-10 billion /mL, 20-1 billion/mL, 25-10 billion/mL, 25-1 billion/mL, 30-10 billion/mL, 30 million ~1 billion/mL, 35-10 billion/mL, 35-1 billion/mL, 50-10 billion/mL, 50-1 billion/mL , 75-10 billion/mL, 75-1 billion/mL, 100-10 billion/mL, 100-1 billion/mL, 150-100 150-1 billion/mL, 200-10 billion/mL, 200-1 billion/mL, 250-10 billion/mL, 200-5 10 million to 1 billion cells/mL and the like.

The temperature of the body cooling liquid of the present invention can be appropriately set according to the condition of the body part to be cooled, the cooling purpose, etc. For example, 0 to 10°C, 0 to 8°C, 0 to 6°C, ~4°C, 0-3°C, 0-2°C, 2-10°C, 2-8°C, 2-6°C, 2-4°C, 4-10°C, 4-8°C, 4-6°C, etc. mentioned.

The method for producing the body cooling liquid of the present invention is as described in "2." above.

The body coolant of the present invention may be contained in a container. The shape and material of the container are not particularly limited, and examples thereof include a plastic bottle container.

4. <Body cooling method of the present invention>
The body cooling method of the present invention is a method for cooling the body of an animal, preferably a method for cooling the body of an animal while suppressing a decrease in blood flow in the body of the animal. As the body cooling method of the present invention, CO2 _- rich ice (preferably _CO2 hydrate), the body cooling agent or body cooling liquid of the present invention is applied to the whole body or local skin of an animal (e.g., non-human animal). is not particularly limited as long as it includes a step applied to.

As a method of applying (e.g., contacting) the CO2 _- enriched ice (preferably _CO2 hydrate), body cooling agent or body cooling liquid of the present invention to the whole body or local skin of an animal, _CO2- enriched A method of contacting ice (preferably CO ₂ hydrate) or the blood flow promoting agent of the present invention with the skin of the application site, a method of immersing the skin of the application site in the blood flow promoting liquid of the present invention, the skin of the application site Preferable examples include a method of applying the blood flow promoting liquid of the present invention, and among them, a method of immersing the skin at the application site in the blood flow promoting liquid of the present invention is more preferred.

5. <Other aspects of the present invention>
The present invention also includes the following aspects.
CO2 _- enriched ice (preferably CO2 hydrate) for cooling the body of _an animal (preferably for cooling the body of an animal while suppressing a decrease in blood flow), the body cooling of the present invention use of medications or body coolants;
For cooling the animal's body (preferably for cooling the animal's body while suppressing the decrease in blood flow), CO2 _- rich ice (preferably _CO2 hydrate), the body cooling of the present invention a method of using an agent or body coolant;
CO2 _- enriched ice (preferably _CO2 hydrate), body cooling agents or body cooling liquids according to the invention, for use in the treatment of diseases requiring cooling of the body;
use of CO2 _- enriched ice (preferably _CO2 hydrate) in the manufacture of a body coolant or body coolant according to the invention;

EXAMPLES The present invention will be described in detail below with reference to Examples, but the present invention is not limited to these Examples.

Test 1. [Preparation of _CO2 hydrate]
Preparation of _CO2 hydrate _CO2 gas is blown into 4 L of water to 3 MPa, and the _CO2 hydrate production reaction is allowed to proceed at 1 ° C with stirring, and the _CO2 hydrate particles are suspended in the water. A " _CO2 hydrate slurry" was obtained. The slurry was poured into a cylinder-type compression molding machine and compressed for 3 minutes at a compression pressure of 2 MPa. After cooling to −20° C., cylindrical lumps of compacted CO ₂ hydrate were recovered from the compaction machine and then crushed. A polyhedral-shaped compacted CO ₂ hydrate with a maximum length of ≧3 mm and ≦60 mm was selected and collected and used in subsequent experiments. It should be noted that the _CO2 content of this compacted _CO2 hydrate was 24% and the _CO2 hydrate rate was about 85%.

Test 2. [Concentration and particle size of ultra-fine bubbles in water containing _CO2 hydrate]
The concentration and particle size of ultra-fine bubbles in CO ₂ hydrate-containing ice water obtained by adding CO ₂ hydrate to water were measured and compared with the concentration and particle size of ultra-fine bubbles in artificial carbonated ice water and plain ice water.

(1) Preparation of each sample To 5 mL of water (approximately 26°C), add 1.5 g of CO ₂ hydrate (approximately -80°C) prepared in Test 1, and add ice water containing CO ₂ hydrate (0 to 2° C.) (carbonic acid concentration of 1000 ppm or more) was prepared.

Artificial carbonated ice water (0 to 2°C) (carbonic acid concentration of 1000 ppm or more) was prepared by adding carbon dioxide to 5 mL of ice water using an artificial carbonated spring production device ("Cleansui", manufactured by Mitsubishi Chemical Corporation) and a carbon dioxide cylinder.

Plain ice water (0-2° C.) was provided.

(2) Measurement of concentration and particle size of ultra-fine bubbles For ice water containing CO ₂ hydrate, artificial carbonated ice water, and plain ice water prepared in (1) above, bubbles were measured using Malvern's "Nanosite NS300". was measured for concentration and particle size. Fig. 1 shows the particle size distribution and number concentration (cells/mL) of bubbles in ice water containing _CO2 hydrate.

As shown in Fig. 1, it was confirmed that _CO2 ultra-fine bubbles were generated in water by adding _CO2 hydrate to water. In the present CO ₂ hydrate-containing ice water (0-2°C), ultra-fine bubbles with a concentration of 550 million/mL were generated, and the median particle size was 125 nm. The concentration of ultra-fine bubbles in simple ice water was 0.036 million/mL, and the concentration of ultra-fine bubbles in artificial carbonated ice water was 0.046 million/mL. These results indicate that the concentration of ultra-fine bubbles in artificial carbonated ice water is less than 1/100 of that in ice water containing _CO2 hydrate.

Test 3. [Confirmation of the effect of CO ₂ hydrate in suppressing the decrease in blood flow]
The following experiments were performed to determine the effects of CO ₂ hydrate-containing ice water on the skin blood flow of animals when applied to the skin.

(1) Preparation of each sample ice water To 150 mL of water at 26 ° _{C, add 45 g of CO 2 hydrate} prepared in Test 1 (about -80 ° C), (carbonic acid concentration of 1000 ppm or more) was prepared.

Carbon dioxide gas is added to ice water obtained by adding 45 g of ice to 150 mL of water at 26 ° C. using an artificial carbonated spring manufacturing device (“Cleansui”, manufactured by Mitsubishi Chemical Corporation) and a carbon dioxide gas cylinder, and artificial carbonated ice water (0 to 2° C.) (carbonic acid concentration of 1000 ppm or more) was prepared.

Simple ice water (0-2°C) was prepared by adding 45 g of ice to 150 mL of water at 26°C.

(2) Blood flow measurement test In the blood flow measurement test, Wistar strain males weighing about 300 g were bred for one week in a constant temperature animal room at 24°C under a 12-hour light-dark cycle (lights on from 8:00 to 20:00). rats were used. Blood flow was measured by fixing a probe (diameter 1 cm) of a laser blood flow meter (ALF21, manufactured by Advance) near the origin of the dorsal surface of the rat tail with surgical tape to measure blood flow (mL/ml). minutes/100 g of tissue) were measured.

When the blood flow data of the rat became stable, the blood flow of the tail skin was measured while the rat tail was immersed in the ice water of each sample prepared in (1) above for 30 minutes. After that, each sample ice water was removed from the tail, and the blood flow of the skin of the tail was measured for 30 minutes. The tail was immersed in the sample ice water so that the probe was positioned slightly above the immersed portion of the tail, since the measured value would be shifted if the probe of the blood flowmeter came into contact with the sample ice water. During the blood flow measurement test, body temperature (rat rectal temperature) was kept at 37.0±0.5° C. with a heat retaining device. Blood flow data were collected using a Power-Lab analog-to-digital converter. Percentage of blood flow data, which is the average value of blood flow (ml/min/100 g of tissue) every 5 minutes, and the average value (0 minute value) for 5 minutes before the start of immersion of the tail in the sample ice water is taken as 100%. represented by It was confirmed with a thermometer that the temperature of each sample ice water was maintained at 0 to 2° C. during the 30 minutes in which the tail was immersed in each sample ice water. The results of such a blood flow measurement test are shown in FIG.

As shown in FIG. 2, when the tail is immersed in simple ice water ("ice water"), the blood flow in the skin of the tail gradually decreases, reaching a minimum value of 66.0% 30 minutes after the start of immersion. , the blood flow remained at a value close to that value until 60 minutes after the start of immersion (that is, 30 minutes after the end of immersion), and reached 67.1% 30 minutes after the end of immersion.

On the other hand, when the tail is immersed in artificial carbonated ice water, the blood flow in the skin of the tail gradually decreases, reaching 80.0% 15 minutes after the start of immersion, and after that, it stays around that value, and the immersion starts. 45 minutes after the end of immersion (that is, 15 minutes after the end of immersion), the lowest value was 75.7%. ) to 88.5%.

On the other hand, when the tail is immersed in ice water containing _CO2 hydrate, the blood flow in the skin of the tail slightly increases as a whole, and even after removing the ice water containing _CO2 hydrate from the tail, the blood flow before the start of immersion ( 100%). The maximum blood flow (107.4%) was measured 60 minutes after the start of immersion (that is, 30 minutes after the end of immersion).

These results suggest that applying a cryogenic liquid containing _CO2 hydrate (e.g., ice water containing _CO2 hydrate) to the skin of an animal body cools the body while suppressing the decrease in blood flow in the skin. proved that it can be done. It has been proved that such an effect cannot be achieved with mere low-temperature water (for example, simple ice water), nor can it be achieved with a low-temperature artificial carbonated spring (for example, artificial carbonated ice water). From these facts, icing the body with a low-temperature liquid containing ice with a CO ₂ content of 3% by weight or more (preferably CO ₂ hydrate) reduces blood flow, which has been a problem with conventional icing methods. can be suppressed, and as a result, it is thought that cooling has the effect of suppressing inflammation, removing fatigue substances, and maintaining exercise performance.

INDUSTRIAL APPLICABILITY According to the present invention, there are provided a body cooling agent that can cool the body while suppressing a decrease in blood flow, and a method for producing a body cooling liquid that includes a step of bringing the body cooling agent into contact with a liquid. be able to.

Claims (7)

Body cooling agent, characterized in that it contains ice with a _CO2 content of 3% by weight or more. A body cooling agent according to claim 1, wherein the ice with a _CO2 content of 3% by weight or more is a _CO2 hydrate. 3. The body cooling agent according to claim 1 or 2, wherein the ice with a CO2 content of 3% by weight or more has a maximum length of 3 mm or more and _a CO2 content of 3% by weight _or more. Ice with a CO ₂ content of 3% by weight or more generates ultra-fine bubbles in water so that the concentration of ultra-fine bubbles is 5 million bubbles / mL or more when measured by the following measurement method R1. The body cooling agent according to any one of claims 1 to 3, characterized in that it is ice that can be cooled.
(Measurement method R1)
300 mg/mL of ice having a temperature of −80 to 0° C. and having a CO ₂ content of 3% by weight or more is added to water at 25° C. to contain ice having a CO ₂ content of 3% by weight or more. After making ice water at 0 to 2° C., the concentration (number/mL) of ultra-fine bubbles in the ice water is measured. Body cooling agent according to any one of claims 1 to 4, characterized in that the ice with a CO ₂ content of 3% by weight or more is compacted CO ₂ hydrate. 6. The body cooling agent according to any one of claims 1 to 5, which is for preparing a body cooling liquid for application to the skin just before use. A method of producing a body coolant for application to skin (but not human skin) comprising the step of contacting a body coolant according to any one of claims 1 to 6 with a liquid.

Images